Amneal Pharmaceuticals, Inc. (AMRX) Revenue History
Annual and quarterly revenue from 2015 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
AMRX Revenue Growth
Revenue Breakdown (FY 2024)
AMRX's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
AMRX Revenue Analysis (2015–2025)
As of May 8, 2026, Amneal Pharmaceuticals, Inc. (AMRX) generated trailing twelve-month (TTM) revenue of $3.02 billion, reflecting strong growth of +11.5% year-over-year. The most recent quarter (Q4 2025) recorded $814.3 million in revenue, up 3.8% sequentially.
Looking at the longer-term picture, AMRX's 5-year compound annual growth rate (CAGR) stands at +8.7%, indicating steady revenue expansion. The company achieved its highest annual revenue of $3.02 billion in 2025, representing a new all-time high.
Revenue diversification analysis shows AMRX's business is primarily driven by Specialty Segment (100%). With over half of revenue concentrated in Specialty Segment, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including TEVA (+4.4% YoY), VTRS (+1.6% YoY), and PRGO (-3.6% YoY), AMRX has underperformed the peer group in terms of revenue growth. Compare AMRX vs TEVA →
AMRX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| AMRXCurrent | $3.0B | +11.5% | +8.7% | -0.2% | |
 TEVA | $17.3B | +4.4% | +0.7% | 12.5% | |
 VTRS | $14.3B | +1.6% | +3.7% | -18.6% | |
 PRGO | $4.3B | -3.6% | +0.8% | 8.1% | |
 PAHC | $1.3B | +32.4% | +10.1% | 8.5% |
AMRX Historical Revenue Data (2015–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $3.02B | +8.0% | $1.11B | 36.9% | $-5,240,000 | -0.2% |
| 2024 | $2.79B | +16.7% | $1.02B | 36.5% | $249.3M | 8.9% |
| 2023 | $2.39B | +8.2% | $863.9M | 36.1% | $204.4M | 8.5% |
| 2022 | $2.21B | +5.7% | $791.5M | 35.8% | $-94,928,000 | -4.3% |
| 2021 | $2.09B | +5.1% | $769.0M | 36.7% | $152.7M | 7.3% |
| 2020 | $1.99B | +22.5% | $628.4M | 31.5% | $91.2M | 4.6% |
| 2019 | $1.63B | -2.2% | $353.0M | 21.7% | $-248,682,000 | -15.3% |
| 2018 | $1.66B | +60.9% | $716.4M | 43.1% | $-19,673,000 | -1.2% |
| 2017 | $1.03B | +1.5% | $526.2M | 50.9% | $245.1M | 23.7% |
| 2016 | $1.02B | +17.5% | $597.5M | 58.7% | $284.9M | 28.0% |
See AMRX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs AMRX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare AMRX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonAMRX — Frequently Asked Questions
Quick answers to the most common questions about buying AMRX stock.
Is AMRX's revenue growth accelerating or slowing?
AMRX maintains +11.5% revenue growth, in line with its 5-year CAGR of +8.7%. TTM revenue stands at $3.0B. Growth rate remains consistent with historical average.
What is AMRX's long-term revenue growth rate?
Amneal Pharmaceuticals, Inc.'s 5-year revenue CAGR of +8.7% reflects the sustained expansion pattern. Current YoY growth of +11.5% is near this long-term average.
How is AMRX's revenue distributed by segment?
AMRX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2015-2025 are available for download. Segment mix reveals concentration and diversification trends.